Thus, to determine whether weekly MIS416 administration caused a similar consistent elevation in serum IFN-γ levels as we observed in mice, we assessed IFN-γ levels in the serum of secondary progressive MS patients enrolled for a phase 1b/2a study designed to confirm the recommended dose of MIS416 and establish its safety profile. Here, IFNG is linked to myeloid sarcoma.